Sanofi is a world-leading medical and health company headquartered in Paris, France that researches, develops and promotes innovative treatment solutions based on the needs of patients.

Sanofi’s main business covers three main areas: pharmaceuticals, human vaccines and animal health. Sanofi has been in China for 38 years and has roots in more than 2,000 counties and cities in the country.

It was one of the first multinational pharmaceutical companies to enter China and has introduced more than 40 high-quality innovative drugs and vaccines to the Chinese people. Its diversified treatment plans cover seven of the top 10 deadly diseases in China.

In 1995, Sanofi’s Beijing production base was officially established in the Beijing Economic-Technological Development Area (BDA).

In 2020, Sanofi (Beijing) Pharmaceutical signed an agreement with BDA to start a new production line for insulin glargine injections. The total investment in the project is 200 million yuan.

The existing production line will be upgraded and new assembly and packaging production lines will be added. The assembly line is expected to be put into operation in 2022, and the filling line will be put into operation in 2024.

After the completion of the production line, the production capacity should reach 48 million pieces per year.

In June 2021, the signing ceremony for the insulin manufacturing expansion project of Sanofi’s Beijing production base and the 25th anniversary celebration of the Beijing factory was held in the factory area, located in BDA.

After 25 years of continuous investment, expansion and upgrades, it now has some the world’s most advanced insulin production lines, such as the insulin glargine injection filling line, which fully meets the sugar control needs and medication safety of Chinese diabetic patients.